SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:DiVA.org:uu-204091"
 

Sökning: id:"swepub:oai:DiVA.org:uu-204091" > Projected cost-effe...

Projected cost-effectiveness of repeat high-risk human papillomavirus testing using self-collected vaginal samples in the Swedish cervical cancer screening program

Ostensson, Ellinor (författare)
Karolinska Institutet
Hellstrom, Ann-Cathrin (författare)
Karolinska Institutet
Hellman, Kristina (författare)
Karolinska Institutet
visa fler...
Gustavsson, Inger (författare)
Uppsala universitet,Genomik
Gyllensten, Ulf (författare)
Uppsala universitet,Genomik
Wilander, Erik (författare)
Uppsala universitet,Obstetrik & gynekologi
Zethraeus, Niklas (författare)
Karolinska Institutet
Andersson, Sonia (författare)
Karolinska Institutet
visa färre...
 (creator_code:org_t)
2013-04-22
2013
Engelska.
Ingår i: Acta Obstetricia et Gynecologica Scandinavica. - : Wiley. - 0001-6349 .- 1600-0412. ; 92:7, s. 830-840
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Background Human papillomavirus (HPV) testing is not currently used in primary cervical cancer screening in Sweden, and corresponding cost-effectiveness is unclear. Objective From a societal perspective, to evaluate the cost-effectiveness of high-risk (HR)-HPV testing using self-collected vaginal samples. Design A cost-effectiveness analysis. Setting The Swedish organized cervical cancer screening program. Methods We constructed a model to simulate the natural history of cervical cancer using Swedish data on cervical cancer risk. For the base-case analysis we evaluated two screening strategies with different screening intervals: (i) cytology screening throughout the woman's lifetime (i.e. conventional cytology strategy) and (ii) conventional cytology screening until age 35years, followed by HR-HPV testing using self-collected vaginal samples in women aged 35years (i.e. combination strategy). Sensitivity analyses were performed, varying model parameters over a significant range of values to identify cost-effective screening strategies. Main outcome measures Average lifetime cost, discounted and undiscounted life-years gained, reduction in cervical cancer risk, incremental cost-effectiveness ratios with and without the cost of added life-years. Results Depending on screening interval, the incremental cost-effectiveness ratios for the combination strategy ranged from Euro43000 to Euro180000 per life-years gained without the cost of added life-years, and from Euro74000 to Euro206000 with costs of added life-years included. Conclusion The combination strategy with a 5-year screening interval is potentially cost-effective compared with no screening, and with current screening practice when using a threshold value of Euro80000 per life-years gained.

Nyckelord

Cervical cancer
cost-effectiveness
human papillomavirus (HPV)
screening
self-sampling

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy